Enzo arbeitet an AIDS Medikament - 500 Beiträge pro Seite

[boardbroker]

Hat jemand Infos über Enzo Biotech (NYSE)?

[Skydiver-]

Enzo Biochem Reports Researchers Using Its Technology Successfully Suppressed Human Liver Cancer in Mice; Sees Significant Application for Treating Humans
Business Wire - Monday, October 30, 2000


DALLAS--(BUSINESS WIRE)--Oct. 30, 2000--Enzo Biochem, Inc., (NYSE:ENZ), reported today that in preclinical animal studies of the Company`s proprietary immune regulation product, EHT899, researchers in Israel had achieved complete suppression of HBV-associated human liver cancer and significantly reduced mortality in laboratory mice. Enzo said that the studies may have significant potential application for treatment of liver and other cancers in humans.

The research results were presented in a paper delivered at a plenary session of the American Association for the Study of Liver Diseases meeting here this week. The study was conducted by researchers at the Liver Unit at the Hadassah University Medical Center in Jerusalem, Israel in collaboration with Enzo scientists.

There is currently no effective treatment for HBV-associated liver cancer. In previous studies, the Hadassah-Enzo team had shown that it is possible to augment an anti-HBV immune response by oral administration of EHT899, Enzo`s proprietary medicine for HBV that is currently in a Phase II clinical trial. "The present study has shown that the growth of human liver cancer in mice could be suppressed by oral administration of EHT899," said Dean L. Engelhardt, Ph.D., Executive Vice President of Enzo. "This procedure resulted in an enhanced immune response to the human tumor in the mice."

In these experiments, the researchers injected athymic mice (mice having no immune system) with human hepatoma (liver cancer) cells. The experimental mice were then transplanted with immune cells from donor mice that had been immune regulated by EHT899. The control mice were transplanted with immune cells from donor mice that had not been immune regulated. In the experimental mice that received the immune regulated cells, total suppression of the tumor was observed, along with significantly reduced mortality. In control mice transplanted with non immune regulated cells tumor growth occurred, leading to 100% mortality. "Induction of oral immune regulation by EHT899 appears to enhance the anti-tumor immunological response, thus suppressing the growth of hepatocellular (liver) carcinoma in mice," commented Dr. Engelhardt. "These findings may have significant application for treatment of liver cancer in humans."

"Our next step is to consider clinical studies, given the strong results we observed in these animal experiments," said Dr. Engelhardt. "This research demonstrates the effective use of our immune regulation strategy in suppressing HBV-associated liver cancer. This hopeful development requires further exploration."

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

A conference call conducted by Enzo Biochem, Inc. management will take place on Tuesday October 31,2000 at 9 A.M. (ET) over the Internet through Investor Broadcast Networks` Vcall website, located at www.vcall.com. To listen to the live call, please go to the web site at least fifteen minutes early to register, download and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available shortly after the call.

Except for historical information, the matters discussed in this news release may be considered `forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.


CONTACT: Anreder Hirschhorn Silver and Company, New York
Steve Anreder, 212/532-3232

Kurs $ 38.69

[Skydiver-]

Enzo Biochem says drug suppresses liver cancer in mice
MONDAY, OCTOBER 30, 2000 8:29 AM
- Reuters

DALLAS, Oct 30 (Reuters) - Biotechnology company Enzo Biochem Inc. (NYSE:ENZ) on Monday said its immune regulation product had reduced mortality and completely suppressed HBV-associated human liver cancer in laboratory mice.

Enzo said the studies may have significant potential application for treatment of liver and other cancers in humans. Currently, there is no effective treatment for HBV-associated liver cancer, the company noted.

Enzo`s product, EHT899, is currently in Phase II clinical trial. The recent study showed that taken orally, EHT899 was able to suppress growth of human liver cancer in mice. The procedure resulted in an enhanced immune response to the human tumour, Enzo said.

In the experiments, researchers injected human liver cancer cells into mice with no immune system. The experimental mice were then transplanted with immune cells from donor mice that had been immune regulated by the Enzo medicine. Another group of mice were transplanted with immune cells from donors that had not been immune regulated. The experimental group of mice that received immune regulated cells showed total suppression of the tumour and reduced mortality. The other group of mice with non-immune regulated cells all died, Enzo said.

The research results were presented at the American Association for the Study of Liver Diseases meeting in Dallas. The study was conducted by researchers at Hadassah University Medical Centre in Jerusalem with Enzo scientists.

Rtr 08:29 10-30-00

Selector Code: reuco

Copyright 2000, Reuters News Service

[Skydiver-]

ENZO BIOCHEM INC (ENZ)
10/30/2000 09:49:28, ET
Exchange NYSE Volume 34000
Last 41.1875 Change +2.5000
Bid 41.1875 Bidsize 3
Ask 41.5000 Asksize 5
High 42.0000 Low 40.5625

[cabinda]

Falls es jemand noch nicht gemerkt hat: Enzo Biotech/ENZ mag eine interessante Aktie sein, hat aber mit Enzon nichts zu tun:

Enzon = ENZN, WKN 873997.

Vielleicht kann ja jemand zur Ergänzung mal die WKN von Enzo Biotech hineinstellen.

[chini]

Schau Dir mal Vaxgen an.
Vaxgen ist weltweit die einzige Firma mit einem Aids - Impfstoff
in Phase 3 und ist lt. eigenen Angaben der Konkurrenz um 4 Jahre
voraus.
Weitere Infos im Vaxgen-Thread
Gruss
chini